ADIL
NASDAQAdial Pharmaceuticals Inc
News · 26 weeks36+133%
2025-12-282026-06-21
Mix2090d
- Insider10(50%)
- Other5(25%)
- SEC Filings4(20%)
- Offering1(5%)
Latest news
25 items- PRAdial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE FinancingGLEN ALLEN, Va., June 16, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company") today announced that the Company's Compensation Committee and Board of Directors granted Matthew Davidson and Julie Saiki, the Company's newly appointed chief development officer and executive vice president of strategy, respectively, restricted stock units and stock options to purchase Company common stock as an inducement to them becoming employees of the Company in connection with the closing of its business combination with Azora Therapeutics, Inc. ("Azora"), which was previously announced by the Company on June 11, 2026. Additionally, the Company today announced the
- INSIDERChief Development Officer Davidson Matt was granted 297,491 shares and was granted 1,923 units of Series A Preferred Stock (SEC Form 4)4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
- INSIDERSEC Form 3 filed by new insider Davidson Matt3 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
- INSIDERSEC Form 4 filed by Director Young Wendy B.4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
- INSIDERSEC Form 3 filed by new insider Young Wendy B.3 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
- SECAdial Pharmaceuticals Inc filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Leadership Update, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- PRAdial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing- Acquisition of Azora and concurrent private placement positions the combined company to advance its pipeline through key clinical milestones in ulcerative colitis, including Phase 1 initiation in mid-2027 - Azora's oral candidate, AT177, is a novel, colon‑targeted AhR agonist rationally engineered to have minimal systemic exposure and designed to mitigate safety concerns with systemically absorbed AhR agonists - $32 million in upfront financing with the potential to receive an additional $32 million under additional milestone tranches - Adial to host a conference call today, June 11, 2026 at 1pm ET GLEN ALLEN, Va. and LOS ANGELES, June 11, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceutica
- SECAdial Pharmaceuticals Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- PRAdial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business UpdateGLEN ALLEN, Va., May 11, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2026 first quarter ended March 31, 2026. "We are very encouraged by the continued progress we have made in early 2026 to advance AD04 toward late-stage development, particularly in light of several important regulatory and strategic developments that we believe meaningfully strengthen our path forward," said Cary Claiborne, Chief Executive Officer of Adia
- SECSEC Form 10-Q filed by Adial Pharmaceuticals Inc10-Q - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- PRAdial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045GLEN ALLEN, Va., April 29, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the filing of a new U.S. utility application with the United States Patent and Trade Office (USPTO) directed to AD04, the Company's lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. Once the patent is granted, it is expected to protect Adial's core assets through at least 2045. The application
- PRAdial Pharmaceuticals Submits Application to FDA Commissioner's National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development ProgramGLEN ALLEN, Va., April 27, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the submission of the AD04 product application for consideration of the Food & Drug Administration (FDA) Commissioner's National Priority Voucher Pilot Program (CNPV). Announced in 2025, the CNPV program is designed to speed up the FDA review process for drugs that address one of five key U.S. national health priorities. It uses a collaborative review approach—similar to a "tumor board," where experts meet to discuss
- PRAdial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 TrialGLEN ALLEN, Va., April 22, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the successful completion of the demonstration batch production for AD04. The results of the batch confirmed that the transferred process met the targeted specifications for the planned Phase 3 clinical batch (and registration campaign) and matched the dissolution profile of the previous Phase 2 batch, thereby demonstrating a successful technical process transfer. This important step was required prior to manufacturing
- INSIDERSEC Form 4 filed by Anderson J. Kermit4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
- SECAdial Pharmaceuticals Inc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- INSIDERSEC Form 4 filed by Goodman Tony4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
- INSIDERSEC Form 4 filed by Shah Vinay4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
- INSIDERSEC Form 4 filed by Schuyler Kevin4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
- INSIDERSEC Form 4 filed by Claiborne Cary J4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
- INSIDERSEC Form 4 filed by Gilliland Robertson H.4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
- PRAdial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for VeteransGLEN ALLEN, Va., March 24, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction and related disorders, today commended members of the U.S. Congress for introducing H.R. 7091, the Expanding Veterans' Access to Emerging Treatments Act, bipartisan legislation aimed at expanding research and development of emerging therapies for conditions affecting U.S. veterans, specifically including Alcohol Use Disorder (AUD). Alcohol Use Disorder remains a significant issue within the veteran population, with nearly 40% of veterans experiencing AUD at some point in t
- SECAdial Pharmaceuticals Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- PRAdial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business UpdateGLEN ALLEN, Va., March 06, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2025 fiscal year ended December 31, 2025. Key Highlights: Regulatory Progress: Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04's pharmacologic profile and regulatory strategy.Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company's proposed in vitro bri
- SECSEC Form 10-K filed by Adial Pharmaceuticals Inc10-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
- SECAdial Pharmaceuticals Inc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
ADIL FAQ
7 questionsWhat does Adial Pharmaceuticals Inc do?
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in phase 3 clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Charlottesville, Virginia.Where does ADIL stock trade?
Adial Pharmaceuticals Inc (ADIL) is listed on NASDAQ.What sector and industry is ADIL in?
Adial Pharmaceuticals Inc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Adial Pharmaceuticals Inc go public?
Adial Pharmaceuticals Inc (ADIL) completed its IPO in 2018.What are analysts saying about ADIL?
Adial Pharmaceuticals Inc has had 3 recent analyst actions on file. The most recent action was from Rodman & Renshaw: Buy with a $800.00 price target on 2024-11-14. Recent price targets range from $500.00 to $1200.00.What companies are similar to ADIL?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ADIL side-by-side with any of them on Quantisnow.How can I track ADIL on Quantisnow?
Quantisnow aggregates Adial Pharmaceuticals Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ADIL to receive live email and push alerts on every new disclosure.